Endovascular Treatment for Stroke From a Blocked Basilar Artery With a Large Core Infarction
Tests a clot-removal procedure versus medical care in adults with this stroke.
Plain-language title generated from the registry record
Registry title: The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with a stroke caused by a blocked basilar artery in the back of the brain and a large area of damaged tissue.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute stroke in the back of the brain, within 24 hours of onset. The basilar artery is blocked (confirmed by CTA, MRA or DSA). Large core infarction: pc-ASPECTS of 5 or lower, or Pons-Midbrain Index of 3 or higher. NIHSS score of 10 or higher before randomization.
- Earlier treatment
- Before the stroke, daily life was mostly independent (pre-stroke mRS of 0 to 2). People already in, or expecting to join, another drug or device trial within 3 months cannot join.
Main reasons for not taking part
- Signs of bleeding in the brain on imaging, except microbleeds
- Pregnant or breast-feeding
- Blood pressure above 220 systolic or 110 diastolic that drugs cannot control
- Life expectancy under 1 year
- Known bleeding tendency, or blood thinner tablets with INR above 1.7
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07333950, who can take part
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaContact: Feng Gao, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07333950
- Record updated
- 12 January 2026
- Original description
This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trialRead full original descriptionShow less
The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial
This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial
Inclusion: The age ranged from 18 to 80 years; Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours; Acute basilar artery occlusion confirmed by CTA,MRA,or DSA; Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≤5, or Pons-Midbrain Index (PMI)≥3; NIHSS score ≥10 before randomization; Pre-stroke mRS of 0-2; Each patient or their legal representative must provide written informed consent before enrolment.
Exclusion: Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization; Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months; Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group); History of contraindication for contrast medium (except mild rash); Refractory hypertension (defined as systolic blood pressure>220 mmHg or diastolic blood pressure>110 mmHg) that cannot be controlled by drug treatment; Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up; It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up; Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.); Any other condition (in the opinion of the site investigator) that inappropriate to participate this study; Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR>1.7; Blood glucose<2.7 or>22.2 mmol/L; Platelet count<50×109/L, glomerular filtration rate<30ml/min or serum creatinine ≥ 3 mg/dl; Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging; Known or highly suspected chronic occlusion of basilar artery; Current pregnant or breast-feeding; CTA/MRA/DSA confirmed occlusion of anterior and posterior circulation; Central nervous system vasculitis has been diagnosed or clinically suspected.